0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2006;296(11):1323. doi:10.1001/jama.296.11.1323.
Text Size: A A A
Published online

FETAL AND INFANT SURVIVAL FOLLOWING PREECLAMPSIA

Induced preterm delivery is common in pregnancies complicated by preeclampsia, but little is known about the effects of early delivery on fetal and infant survival. Basso and colleagues analyzed data from 1967 to 2003 for singleton first-born infants of Norwegian-born mothers to assess fetal and infant survival following early delivery of preeclamptic pregnancies. Comparing data from 1967-1978 with that from 1991-2003, the authors found a significant increase in the rate of preterm inductions for preeclampsia, a reduction in the risk of stillbirth in preeclamptic vs nonpreeclamptic pregnancies, and relatively stable risks of neonatal and later infant deaths.

LIPOPROTEIN(A) AND FUTURE CARDIOVASCULAR EVENTS

Whether lipoprotein(a) is a meaningful marker of cardiovascular risk in women is controversial, and part of the controversy could be a consequence of interassay differences. To explore these questions, Suk Danik and colleagues used a state-of-the-art lipoprotein(a) assay to assess the association between baseline lipoprotein(a) levels and incidence of future cardiovascular events in a prospective cohort study of 27 791 women who were healthy at study enrollment. The authors found a significantly increased risk of future cardiovascular events among women with extremely high (≥90th percentile) levels of lipoprotein(a), particularly among women with high levels of low-density lipoprotein cholesterol.

FATTY FISH CONSUMPTION AND RENAL CELL CARCINOMA

Studies examining the association of fatty fish consumption with risk of several cancers have yielded inconsistent results, and no studies have explored fatty fish consumption and risk of renal cell carcinoma (RCC). To address this deficiency, Wolk and colleagues assessed the association of fatty and lean fish consumption with the risk of RCC in a prospective cohort study of Swedish women. Compared with women reporting no fish consumption, the authors found an inverse association between fatty fish consumption of 1 or more servings per week and risk of RCC during a mean 15.3 years of follow-up. No association was found between lean fish consumption and risk of RCC.

REPRESENTATION OF RENAL DISEASE IN TRIALS OF CVD

Patients with renal disease are at high risk of cardiovascular disease (CVD) morbidity and mortality. However, if patients with renal disease are not represented in CVD treatment trials, optimal treatment strategies for these patients will not be identified. Coca and colleagues reviewed 153 CVD treatment trials, published in 1985 through 2005, to assess the representation of patients with renal disease in the trials. The authors found that patients with renal disease were excluded in 56% of the trials, and few trials assessed baseline renal function of trial enrollees or the effect of the intervention in patients with renal disease.

CLINICIAN'S CORNER

Sulmasy discusses the physician's role in ascertaining and responding to terminally ill patients' spiritual beliefs, including the possibility of a miraculous cure.

A PIECE OF MY MIND

“Is it ever appropriate to sacrifice one student's comfort or privacy for the benefit of the group? When should a teacher impose her own ideology—her own solution to a problem—rather than allowing students to stick with their own conclusion?” From “Mistakes.”

MEDICAL NEWS

One year after Hurricane Katrina pummeled New Orleans and the surrounding Gulf Coast, efforts are under way to rebuild a health system that has lost much of its original work force and infrastructure.

FEDERAL POLICY AND HURRICANE KATRINA

Accomplishments and failures in the US federal health policy response to Katrina.

WITHDRAWAL OF SUPPLEMENTAL OXYGEN

Concerns about terminal withdrawal of life-sustaining supplemental oxygen.

APOLOGY IN MEDICINE

The role of apology in clinical practice.

JAMA PATIENT PAGE

For your patients: Information about palliative care.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...